COMPASS Pathways (CMPS) Competitors $5.20 -0.04 (-0.76%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.20 0.00 (0.00%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPS vs. ADPT, DYN, TVTX, MESO, IMCR, APGE, SRPT, VCEL, AUPH, and PAHCShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Adaptive Biotechnologies (ADPT), Dyne Therapeutics (DYN), Travere Therapeutics (TVTX), Mesoblast (MESO), Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Vericel (VCEL), Aurinia Pharmaceuticals (AUPH), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Its Competitors Adaptive Biotechnologies Dyne Therapeutics Travere Therapeutics Mesoblast Immunocore Apogee Therapeutics Sarepta Therapeutics Vericel Aurinia Pharmaceuticals Phibro Animal Health Adaptive Biotechnologies (NASDAQ:ADPT) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer ADPT or CMPS? Adaptive Biotechnologies presently has a consensus target price of $12.38, suggesting a potential downside of 1.86%. COMPASS Pathways has a consensus target price of $16.29, suggesting a potential upside of 213.19%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has stronger earnings and valuation, ADPT or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$205.22M9.36-$159.49M-$0.82-15.38COMPASS PathwaysN/AN/A-$155.12M-$1.84-2.83 Do insiders and institutionals hold more shares of ADPT or CMPS? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, ADPT or CMPS? Adaptive Biotechnologies has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Is ADPT or CMPS more profitable? COMPASS Pathways has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -59.07%. Adaptive Biotechnologies' return on equity of -60.93% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% COMPASS Pathways N/A -87.89%-57.77% Does the media prefer ADPT or CMPS? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than COMPASS Pathways. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 4 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.28 beat Adaptive Biotechnologies' score of 1.21 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAdaptive Biotechnologies beats COMPASS Pathways on 9 of the 15 factors compared between the two stocks. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$502.73M$7.66B$5.84B$10.14BDividend YieldN/A2.76%5.68%4.60%P/E Ratio-2.8375.5875.4125.98Price / SalesN/A42.18515.86180.60Price / CashN/A24.1437.5660.44Price / Book2.307.3512.156.29Net Income-$155.12M$242.04M$3.29B$271.07M7 Day Performance1.17%1.60%0.74%3.87%1 Month Performance22.64%0.94%5.00%5.49%1 Year Performance-28.28%16.26%62.55%25.86% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways3.2369 of 5 stars$5.20-0.8%$16.29+213.2%-28.3%$502.73MN/A-2.83120Positive NewsADPTAdaptive Biotechnologies3.6551 of 5 stars$12.54-2.4%$12.38-1.3%+173.5%$1.91B$178.96M-15.29790Positive NewsDYNDyne Therapeutics3.7914 of 5 stars$13.30-6.5%$34.07+156.1%-61.4%$1.89BN/A-3.45100Positive NewsTVTXTravere Therapeutics2.9782 of 5 stars$21.20-2.0%$33.43+57.7%+74.1%$1.89B$233.18M-10.39460News CoveragePositive NewsAnalyst ForecastMESOMesoblast2.0504 of 5 stars$14.55+1.1%$18.00+23.7%+138.3%$1.86B$17.20M0.0080Positive NewsGap DownIMCRImmunocore2.0432 of 5 stars$36.64-1.5%$56.89+55.3%+5.0%$1.85B$310.20M-91.60320Positive NewsAPGEApogee Therapeutics2.9114 of 5 stars$38.42+1.5%$97.29+153.2%-28.2%$1.77BN/A-9.3091News CoveragePositive NewsSRPTSarepta Therapeutics4.4333 of 5 stars$17.60-5.9%$43.50+147.2%-86.0%$1.72B$1.90B-20.231,372Trending NewsAnalyst ForecastAnalyst RevisionVCELVericel3.0393 of 5 stars$33.22-2.4%$60.40+81.8%-29.8%$1.68B$237.22M276.86300AUPHAurinia Pharmaceuticals2.9023 of 5 stars$12.30-0.8%$12.00-2.4%+81.2%$1.62B$235.13M28.61300News CoveragePositive NewsPAHCPhibro Animal Health4.5296 of 5 stars$39.43-0.1%$28.40-28.0%+80.2%$1.60B$1.30B33.422,475Trending NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies ADPT Competitors DYN Competitors TVTX Competitors MESO Competitors IMCR Competitors APGE Competitors SRPT Competitors VCEL Competitors AUPH Competitors PAHC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPS) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPS Stock Alerts